Takeda Announces New Assignments of Directors

OSAKA, Japan, June 29, 2021, --- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK)

(“Takeda”) today announced new assignment of Directors. The details are as follows;

 

Directors Who are Not Audit and Supervisory Committee Members

 

1. New assignment of Non-Audit and Supervisory Committee Directors effective June 29, 2021;
   
   

Name	Category		Expected Role
Christophe Weber	Internal	Existing	Representative Director, President & Chief Executive Officer
Masato Iwasaki	Internal	Existing	Representative Director, Japan General Affairs
Andrew Plump	Internal	Existing	Director, President, Research & Development
Constantine Saroukos	Internal	Existing	Director, Chief Financial Officer
Masahiro Sakane	External	Existing	External Director, Chair of the Board Meeting
Olivier Bohuon	External	Existing	External Director
Jean-Luc Butel	External	Existing	External Director
Ian Clark	External	Existing	External Director
Yoshiaki Fujimori	External	Existing	External Director
Steven Gillis	External	Existing	External Director
Shiro Kuniya	External	Existing	External Director
Toshiyuki Shiga	External	Existing	External Director

 

2. New assignment of Audit and Supervisory Committee Directors effective June 29, 2021;

 

Name	Category		Expected Role
Koji Hatsukawa	External	-	External Director, Chairperson of Audit and Supervisory Committee
Emiko Higashi	External	-	External Director, Audit and Supervisory Committee Member
Masami Iijima	External	New	External Director, Audit and Supervisory Committee Member
Michel Orsinger	External	-	External Director, Audit and Supervisory Committee Member

 

Koji Hatsukawa, Emiko Higashi, and Michel Orsinger are within their 2-year tenure of Audit and Supervisory Committee Director, and were not subjects for reelection this year.

 

3. New assignment of Compensation committee and Nomination committee effective June 29, 2021;

 

Compensation committee : Emiko Higashi (Chair), Olivier Bohuon, Ian Clark, Yoshiaki Fujimori
Nomination committee : Masahiro Sakane (Chair), Jean-Luc Butel, Steven Gillis,
Toshiyuki Shiga, Michel Orsinger, Christophe Weber (Observer)

 

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven
biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

 

Media Contacts:
Japanese Media
Ryoko Matsumoto
[email protected]
+81 (0) 3-3278-3414

 

Media Outside Japan
Christina Beckerman
[email protected]
+1 (908) 581-4133